UK Mark Hicken, managing director of the UK and Ireland operations of Janssen, the pharmaceutical arm of Johnson & Johnson, highlights the company’s long-standing R&D presence in the UK. He calls for more creativity in HTA processses in a collaborative effort to bring innovation to patients faster. What is the scope…
Spain Ángel Luis Rodríguez de la Cuerda, secretary general of AESEG, the trade association of generic producers in Spain, discusses the initiatives that the organization is undertaking to develop a true generic culture in the country and a new proposal changing the requirement for originator drugs to remain at the same…
India Dr. Hemant Koshia, commissioner of the FDCA Gujarat, the regulatory authority of the state of Gujarat – India’s leading hub for the production of pharmaceutical and healthcare products – provides insights into the global significance of the Gujarat-based pharmaceutical industry, the collaboration initiatives bolstered by the FDCA and the agency’s…
India Dr. Georges Jabre, the recently appointed CEO of Serdia Pharmaceuticals (India) Pvt. Ltd. (an affiliate of the Servier Group) and president of the Healthcare Committee of the Indo-French Chamber of Commerce and Industry (IFCCI), provides insights into some key specificities of India’s healthcare ecosystem as well as his main priorities…
India Yugal Sikri, chairman of the Pharmaceutical Management Program of the prestigious NMIMS University, and with an extremely rich experience in the pharmaceutical industry, explains his mission to build a valuable discussion platform for CEOs and institutions of the industry alike. Such industry efforts will ensure the Indian pharmaceutical industry efficiently…
India Raghuveer Kini, executive director of the Pharmaceuticals Export Promotion Council of India (Pharmexcil) provides insights into the key success factors that have allowed India to become the world’s pharmaceutical hub and gives us his assessment of the recent plateauing of Indian exports as well as an overview of the new…
Canada Referring to the Canadian affiliate of Zimmer Biomet as a “trailblazer”, Dave O’Neil looks back on a successful 2017 for the musculoskeletal healthcare company in Canada. He describes how Zimmer Biomet positions itself as a true partner in driving efficiency in the Canadian healthcare system. 2017 was an eventful year…
Portugal Oscar Gaspar, VP of the Confederation of Portuguese Industry (CIP), president of the Portuguese Association of Private Hospitalization and former secretary of state for health (2009-2011), provides an informative insight into the state of Portugal’s healthcare system. Through compelling suggestions and observations on the current system, Gaspar sheds light on…
UK Terry O’Regan, VP and managing director at Biogen UK and Ireland, discusses the company’s longstanding commitment to the UK, market access issues, and why Biogen is staying the course with developing Alzheimer’s products at a time when many MNCs are winding down their neurology programs. How would you describe Biogen’s…
Canada Looking back on 40 years of commitment to Canada, Servier also celebrates 20 years of R&D activity in the country. On this two-fold anniversary, Frédéric Fasano highlights some of the company’s more recent achievements in terms of portfolio growth and partnering efforts, while also addressing some of the challenges Servier…
Canada Dwight Gorham, president and CEO of Pillar5 Pharma, discusses the unique positioning of the CDMO in the multi-dose preservative free sterile ophthalmics space and stresses the importance of anticipating market trends in order to fuel expansion. Finally, he gives an insight into the importance of honing new skills and how…
India In this exclusive interview, Binish Chudgar, vice-chairman and managing director of Intas, the largest privately-owned Indian pharmaceutical company with sales of over USD 1.7 billion during the last financial year, provides insights into the company’s growth model and M&A approach, as well as his objectives with regards to a large-scale…
See our Cookie Privacy Policy Here